Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 2/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | GUSB | P08236 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28178173 | 0.83 | NCF1 (0.50) | NCF1LMNAL3MBTL1KDM4ETLR8 | |
| SCHEMBL4273454 | 0.76 | NCF1 (0.52) | NCF1LMNAL3MBTL1KDM4ETLR8 | |
| SCHEMBL423902 | 0.76 | CYP1A2 (0.55) | NCF1P2RY12TLR8GUSBTP53 | |
| SCHEMBL7805413 | 0.75 | NCF1 (0.76) | NCF1TLR8GUSB | |
| SCHEMBL28175260 | 0.75 | ADORA1 (0.54) | NCF1P2RY12LMNAL3MBTL1KDM4E | |
| SCHEMBL7810731 | 0.75 | NCF1 (0.51) | NCF1LMNAL3MBTL1KDM4ETLR8 | |
| SCHEMBL18528819 | 0.75 | ALOX15 (0.70) | NCF1P2RY12LMNAKDM4EGUSB | |
| SCHEMBL31389285 | 0.75 | ALOX15 (0.70) | NCF1P2RY12LMNAKDM4EGUSB | |
| SCHEMBL31529344 | 0.74 | LMNA (0.69) | LMNAKDM4ETLR8SMN1; SMN2 | |
| SCHEMBL27310559 | 0.73 | KDM4E (0.53) | L3MBTL1KDM4ESMN1; SMN2MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913745-B2 | Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200339570-A1 | BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10669268-B2 | Bicyclic derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20180258095-A1 | NEW OCTAHYDRO-PYRROLO[3,4-c]-PYRROLE DERIVATIVES AND ANALOGS THEREOF AS AUTOTAXIN INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-09-13 | — | — | US | disclosed |
| US-20180118741-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20170050960-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2017-02-23 | — | — | US | disclosed |
| US-20150353559-A1 | NEW BICYCLIC DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669268-B2 | Bicyclic derivatives | CCNY, BICRA, UQCRB | NCF1 2085/4885P2RY12 2288/4885LMNA 68/4885 |
| US-20170050960-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | NCF1 1669/4885P2RY12 2163/4885LMNA 140/4885 |
| US-10913745-B2 | Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors | ENPP2, TPX2, PRAP1 | NCF1 859/4885P2RY12 4524/4885LMNA 2763/4885 |
| US-20180118741-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | NCF1 1669/4885P2RY12 2163/4885LMNA 140/4885 |
| US-20150353559-A1 | NEW BICYCLIC DERIVATIVES | BICRA, CCNY, UQCRB | NCF1 1669/4885P2RY12 2163/4885LMNA 140/4885 |
| US-20200339570-A1 | BICYCLIC DERIVATIVES | CCNY, BICRA, UQCRB | NCF1 2085/4885P2RY12 2288/4885LMNA 68/4885 |
| US-20180258095-A1 | NEW OCTAHYDRO-PYRROLO[3,4-c]-PYRROLE DERIVATIVES AND ANALOGS THEREOF AS AUTOTAXIN INHIBITORS | ENPP2, TPX2, UACA | NCF1 659/4885P2RY12 4429/4885LMNA 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.